NewEdge Wealth LLC Buys 28,693 Shares of Pfizer Inc. $PFE

NewEdge Wealth LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 36.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 107,756 shares of the biopharmaceutical company’s stock after acquiring an additional 28,693 shares during the quarter. NewEdge Wealth LLC’s holdings in Pfizer were worth $2,683,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Washington Trust Advisors Inc. boosted its position in shares of Pfizer by 1.2% during the fourth quarter. Washington Trust Advisors Inc. now owns 45,253 shares of the biopharmaceutical company’s stock worth $1,127,000 after acquiring an additional 533 shares during the last quarter. Drucker Wealth 3.0 LLC boosted its position in shares of Pfizer by 8.4% during the fourth quarter. Drucker Wealth 3.0 LLC now owns 59,617 shares of the biopharmaceutical company’s stock worth $1,484,000 after acquiring an additional 4,606 shares during the last quarter. Legacy Wealth Managment LLC ID boosted its position in shares of Pfizer by 397.2% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 1,750 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 1,398 shares during the last quarter. F m Investments LLC lifted its position in Pfizer by 163.9% during the fourth quarter. F m Investments LLC now owns 296,956 shares of the biopharmaceutical company’s stock valued at $7,394,000 after purchasing an additional 184,420 shares during the last quarter. Finally, Manning & Napier Advisors LLC bought a new position in Pfizer during the fourth quarter valued at $1,226,000. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on PFE shares. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a research report on Monday, March 9th. Cantor Fitzgerald reiterated a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, February 4th. Citigroup increased their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Zacks Research upgraded shares of Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, HSBC increased their price objective on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $28.74.

Pfizer Trading Up 0.3%

Shares of PFE opened at $25.88 on Wednesday. Pfizer Inc. has a twelve month low of $21.97 and a twelve month high of $28.75. The company has a market cap of $147.51 billion, a P/E ratio of 19.76 and a beta of 0.35. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company’s fifty day simple moving average is $27.05 and its 200-day simple moving average is $26.18.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to the consensus estimate of $13.84 billion. During the same quarter in the prior year, the firm posted $0.92 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts expect that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Several articles argued that Pfizer looks “dirt cheap” and could be a long-term buy, reinforcing the view that the stock may have room to recover as investors focus on valuation and future growth potential. Article Title
• Positive Sentiment: Pfizer and partner Arvinas reached a licensing transaction with Rigel Pharmaceuticals for the breast cancer drug VEPPANU (vepdegestrant), bringing in $85 million upfront and up to $320 million more in milestones plus royalties, which supports future cash flow and validates the asset. Article Title
• Positive Sentiment: Additional coverage highlighted Pfizer’s earnings as stronger than the market expected, suggesting the company’s recent quarter may have been better than the stock’s muted reaction implied. Article Title
• Neutral Sentiment: Commentary on Pfizer’s dividend raised questions about sustainability, but the discussion also noted the yield remains unusually high and could appeal to income-focused investors. Article Title
• Neutral Sentiment: Analysts and market commentators continued to debate Pfizer’s long-term outlook, including whether oncology and next-generation therapies can offset the post-COVID revenue decline. Article Title
• Negative Sentiment: Coverage also noted pressure on vaccine makers from softer U.S. demand and tougher policy conditions, a reminder that Pfizer’s vaccine-related businesses may face ongoing headwinds. Article Title

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.